GlassScriptPhysician profile
Nick N Patel
NPI 1457536377
$15,758.02
in general payments reported to CMS, 2019-2025
40 companies · $4,080 in 2025
The $4,080 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $691 · 2021: $1,682 · 2022: $2,636 · 2023: $2,895 · 2024: $2,866 · 2025: $4,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,456 · Travel and Lodging: $1,147 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,455.57 |
| Travel and Lodging | $1,146.55 |
| Education | $239.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $2,596.57 | 2020-2025 | Wakix |
| Glaxosmithkline, LLC. | $2,422.47 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $2,052.25 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Inspire Medical Systems, INC. | $1,511.52 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $1,376.97 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,030.04 | 2019-2025 | Ofev, Jascayd |
| Axsome Therapeutics, INC. | $605.91 | 2023-2025 | Sunosi |
| Mylan Specialty L.P. | $559.16 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $499.11 | 2021-2025 | Dupixent |
| Electromed, INC. | $463.42 | 2019-2025 | Smartvest |
| Grifols USA, LLC | $410.49 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $392.81 | 2021-2025 | |
| Viatris Specialty LLC | $192.34 | 2025 | Yupelri |
| Baxter Healthcare | $158.26 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Olympus America INC. | $144.45 | 2024 | Spin Vision Video Processor |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $118.62 | 2025 | Qelbree |
| Verona Pharma, INC. | $117.70 | 2025 | Ohtuvayre |
| Avadel Cns Pharmaceuticals, LLC | $114.34 | 2024-2025 | Lumryz |
| Philips North America LLC | $104.20 | 2020-2023 | |
| Amgen INC. | $85.05 | 2022-2024 | Tezspire |
| Merck Sharp & Dohme LLC | $84.19 | 2020-2023 | Belsomra |
| Zoll Respicardia, INC. | $76.85 | 2024 | Remede System |
| Vifor Pharma, INC. | $74.33 | 2025 | Zemaira |
| Phenox INC. | $68.82 | 2022 | |
| Lilly USA, LLC | $64.58 | 2024-2025 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $61.13 | 2023 | Aralast |
| Recordati_rare_diseases_inc. | $59.63 | 2025 | Isturisa |
| 3b Medical, INC. | $43.94 | 2025 | Luna |
| Insmed, INC. | $40.50 | 2023-2025 | Arikayce |
| Zoll Medical Corporation | $36.92 | 2024 | Defibrillator |
| Apria Healthcare LLC | $27.27 | 2021 | |
| Heron Therapeutics, INC. | $26.20 | 2025 | Aponvie |
| Tandem Diabetes Care, INC. | $22.43 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Fisher & Paykel Healthcare INC | $22.06 | 2021 | |
| Genentech USA, INC. | $21.92 | 2019 | |
| Acadia Pharmaceuticals INC | $15.75 | 2025 | Nuplazid |
| Inogen, INC. | $15.17 | 2022 | |
| Nabriva Therapeutics, Plc | $14.88 | 2021 | |
| Ucb, INC. | $13.39 | 2022 | |
| Tactile Systems Technology INC | $12.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nick Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.